Xia X - Search Results

1

Implication of the Akt2/survivin pathway as a critical target in paclitaxel treatment in human ovarian cancer cells.

Weng D, Song X, Xing H, Ma X, Xia X, Weng Y, Zhou J, Xu G, Meng L, Zhu T, Wang S, Ma D. Weng D, et al. Among authors: xia x. Cancer Lett. 2009 Jan 18;273(2):257-65. doi: 10.1016/j.canlet.2008.08.027. Epub 2008 Oct 7. Cancer Lett. 2009. PMID: 18842333

2

Reversal of the malignant phenotype of ovarian cancer A2780 cells through transfection with wild-type PTEN gene.

Wu H, Wang S, Weng D, Xing H, Song X, Zhu T, Xia X, Weng Y, Xu G, Meng L, Zhou J, Ma D. Wu H, et al. Among authors: xia x. Cancer Lett. 2008 Nov 28;271(2):205-14. doi: 10.1016/j.canlet.2008.06.018. Epub 2008 Jul 26. Cancer Lett. 2008. PMID: 18662848

3

Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer.

Liu Y, Xing H, Weng D, Song X, Qin X, Xia X, Weng Y, Liang F, Chen G, Han X, Ma X, Wang S, Zhou J, Xu G, Meng L, Ma D. Liu Y, et al. Among authors: xia x. Cancer Lett. 2009 Feb 8;274(1):47-53. doi: 10.1016/j.canlet.2008.08.037. Epub 2008 Oct 16. Cancer Lett. 2009. PMID: 18929442

4

Synergistic efficacy in human ovarian cancer cells by histone deacetylase inhibitor TSA and proteasome inhibitor PS-341.

Fang Y, Hu Y, Wu P, Wang B, Tian Y, Xia X, Zhang Q, Chen T, Jiang X, Ma Q, Xu G, Wang S, Zhou J, Ma D, Meng L. Fang Y, et al. Among authors: xia x. Cancer Invest. 2011 May;29(4):247-52. doi: 10.3109/07357907.2010.496756. Epub 2011 Feb 23. Cancer Invest. 2011. PMID: 21345073 Free article.

5

Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.

Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q. Ji T, et al. Among authors: xia x. Cancer Lett. 2013 Dec 1;341(2):231-9. doi: 10.1016/j.canlet.2013.08.022. Epub 2013 Aug 17. Cancer Lett. 2013. PMID: 23962558

6

Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma.

Gao Q, Ye F, Xia X, Xing H, Lu Y, Zhou J, Ma D. Gao Q, et al. Among authors: xia x. J Huazhong Univ Sci Technolog Med Sci. 2009 Feb;29(1):59-63. doi: 10.1007/s11596-009-0112-6. Epub 2009 Feb 18. J Huazhong Univ Sci Technolog Med Sci. 2009. PMID: 19224164

7

Cytoplasmic p21 is a potential predictor for cisplatin sensitivity in ovarian cancer.

Xia X, Ma Q, Li X, Ji T, Chen P, Xu H, Li K, Fang Y, Weng D, Weng Y, Liao S, Han Z, Liu R, Zhu T, Wang S, Xu G, Meng L, Zhou J, Ma D. Xia X, et al. BMC Cancer. 2011 Sep 21;11:399. doi: 10.1186/1471-2407-11-399. BMC Cancer. 2011. PMID: 21933447 Free PMC article.

8

Mesenchymal stem cells as carriers and amplifiers in CRAd delivery to tumors.

Xia X, Ji T, Chen P, Li X, Fang Y, Gao Q, Liao S, You L, Xu H, Ma Q, Wu P, Hu W, Wu M, Cao L, Li K, Weng Y, Han Z, Wei J, Liu R, Wang S, Xu G, Wang D, Zhou J, Ma D. Xia X, et al. Mol Cancer. 2011 Nov 3;10:134. doi: 10.1186/1476-4598-10-134. Mol Cancer. 2011. PMID: 22054049 Free PMC article.

9

Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer.

Wang H, Fan L, Xia X, Rao Y, Ma Q, Yang J, Lu Y, Wang C, Ma D, Huang X. Wang H, et al. Among authors: xia x. Int J Gynecol Cancer. 2012 Jun;22(5):755-61. doi: 10.1097/IGC.0b013e3182540284. Int J Gynecol Cancer. 2012. PMID: 22635028

10

The novel fusion protein sTRAIL-TMTP1 exhibits a targeted inhibition of primary tumors and metastases.

Liu R, Ma X, Wang H, Xi Y, Qian M, Yang W, Luo D, Fan L, Xia X, Zhou J, Meng L, Wang S, Ma D, Xi L. Liu R, et al. Among authors: xia x. J Mol Med (Berl). 2014 Feb;92(2):165-75. doi: 10.1007/s00109-013-1093-2. Epub 2013 Oct 26. J Mol Med (Berl). 2014. PMID: 24158182

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8,327 results

Search Page